Proteins and Peptides

4 May 2015

Allegro Ophthalmics Begins Phase 2 Clinical Study of Luminate® for Non-Proliferative Diabetic Retinopathy

1 May 2015

Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola

1 May 2015

The Medicines Company Announces FDA Approval of RAPLIXA™ (Fibrin Sealant), the First and Only Powdered Fibrin Sealant Ready-to-Use for Mild to Moderate Surgical Bleeding

30 April 2015

Emergent BioSolutions Expands Commercial Product Portfolio With FDA Approval of IXINITY, a Recombinant Factor IX Treatment for Hemophilia B

28 April 2015

Toujeo® Approved in the European Union for the Treatment of Diabetes in Adults

28 April 2015

Synthon Announces Successful Outcomes from the Open-label extension of the Phase III GATE Study of Synthon’s Glatiramer Acetate

28 April 2015

Aeterna Zentaris: Data Safety Monitoring Board Recommends Continuation of Phase 3 Study of Zoptarelin Doxorubicin in Advanced Endometrial Cancer

27 April 2015

Advanced Proteome Therapeutics Reports Successful Fusion Protein Initiative Resulting in APC 103 Which Retards Tumor Growth in an Animal Model

24 April 2015

Actavis Announces Topline Phase 3 Clinical Trial Results for Single-Dose DALVANCE® (dalbavancin) in the Treatment of ABSSSI

23 April 2015

Teva Presents Data Comparing Early Treatment with COPAXONE® 40 mg/mL to Delayed Start Treatment at 67th American Academy of Neurology (AAN) Annual Meeting in Washington, D.C.

23 April 2015

ThromboGenics Starts Evaluating JETREA(r) for the Treatment of Retinal Vein Occlusion (RVO)

23 April 2015

Glide Technologies Completes Successful Proof-of-Concept Study With Novel Solid Dose Formulation of Teriparatide SDI®

21 April 2015

PLEGRIDY® (Peginterferon Beta-1a) Three-Year Data Presented at AAN Annual Meeting Support Long-Term Safety and Efficacy in Multiple Sclerosis Patients

20 April 2015

Halozyme Presents New Preclinical Data At The American Association for Cancer Research Annual Meeting, Announces Clinical Data Presentation At ASCO

20 April 2015

Actavis Announces FDA Approval of Expanded Label for BOTOX® (OnabotulinumtoxinA) for the Treatment of Upper Limb Spasticity in Adults

18 April 2015

Full Data on Baxter’s Investigational Recombinant Treatment BAX 111 Supports Potential Role to Treat von Willebrand Disease

17 April 2015

Eleven Biotherapeutics Presents Phase 2 Clinical Data on EBI-005 for the Treatment of Allergic Conjunctivitis at ASCRS 2015 Annual Meeting

17 April 2015

Sandoz receives FDA approval for GlatopaTM as the first generic competitor to MS therapy Copaxone® 20mg

8 April 2015

Portola Pharmaceuticals Announces New Topline Data From Phase 3 ANNEXA-A(TM) Trial Part 2: Breakthrough Designated Andexanet Alfa Successfully Meets Primary Endpoint for Prolonged Reversal of Factor Xa Inhibitor Eliquis (apixaban)

8 April 2015

Rhythm Initiates Phase 2b Clinical Trial of Relamorelin for Diabetic Gastroparesis

8 April 2015

Ferring announces European approval of new room temperature stable formulation of PABAL® (carbetocin)

8 April 2015

Novo Nordisk – US FDA accepts Tresiba® and Ryzodeg® resubmissions for review

6 April 2015

FDA Expands Indication for EVARREST® Fibrin Sealant Patch

1 April 2015

Oramed Enrolls First Patient in its Glucose Clamp Study for Oral Insulin

1 April 2015

Capricor Therapeutics Completes Enrollment of Phase II Clinical Trial for Cenderitide to Treat Heart Failure

1 April 2015

Protalex Announces FDA Acceptance of Investigational New Drug Application for PRTX-100 to Treat Immune Thrombocytopenia

31 March 2015

Synthetic Biologics Initiates Phase 2a Clinical Trial of SYN-004 to Protect the Microbiome and Prevent C. difficile

31 March 2015

FDA Grants Amgen Priority Review for Kyprolis® (Carfilzomib) Supplemental New Drug Application for the Treatment of Relapsed Multiple Myeloma

31 March 2015

European Medicines Agency Commences Review of CSL Behring’s Regulatory Submission for rIX-FP for Hemophilia B Patients

27 March 2015

Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen’s Epogen

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Report Package: “Drug the Undruggable” Technologies

Omalizumab (Xolair) Biosimilars & Biosuperiors Pipeline Review

CD40 Agonists & CD40/L Antagonists Pipeline Review

2020 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis

Blockbuster Biologics 2018: Sales of Recombinant Therapeutic Antibodies & Proteins

2023 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

2021 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective

Denosumab (Prolia & Xgeva) Biosimilars Pipeline Review